Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.51 |
| ▸ | CNR1 | P21554 | 8/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | JAK1 | P23458 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | CNR2 | P34972 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.43 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4291997 | 0.92 | BRD4 (0.47) | OPRM1CNR1ALDH1A1ALOX15JAK1 | |
| SCHEMBL1054261 | 0.92 | BRD4 (0.47) | OPRM1CNR1ALDH1A1ALOX15JAK1 | |
| SCHEMBL1053495 | 0.84 | JAK1 (0.49) | OPRM1CNR1ALDH1A1ALOX15JAK1 | |
| SCHEMBL6208417 | 0.82 | CNR1 (0.61) | CNR1CNR2CHEK1 | |
| SCHEMBL1055073 | 0.82 | OPRM1 (0.61) | OPRM1CNR1ALDH1A1ALOX15BRD4 | |
| SCHEMBL1054942 | 0.80 | PDGFRB (0.52) | ALDH1A1ALOX15BRD4ATAD2CYP1A2 | |
| SCHEMBL1055067 | 0.78 | OPRM1 (0.57) | OPRM1CNR1ALDH1A1ALOX15CYP1A2 | |
| SCHEMBL4309421 | 0.77 | CNR1 (0.58) | OPRM1CNR1JAK1KDM4ECNR2 | |
| SCHEMBL6188115 | 0.76 | CNR1 (0.46) | CNR1CNR2 | |
| SCHEMBL17025463 | 0.76 | CNR1 (0.82) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140303182-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF QUINOLINONE COMPOUNDS HAVING IMPROVED PHARMACEUTICAL PROPERTIES | NOVARTIS AG (CH) | 2014-10-09 | — | — | US | disclosed |
| US-20130338171-A1 | Pharmaceutically Acceptable Salts of Quinolinone Compounds Having Improved Pharmaceutical Properties | NOVARTIS AG (CH) | 2013-12-19 | — | — | US | disclosed |
| US-20130018058-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF QUINOLINONE COMPOUNDS HAVING IMPROVED PHARMACEUTICAL PROPERTIES | CAI SHAOPEI (US) | 2013-01-17 | — | — | US | disclosed |
| US-20090281100-A1 | Benzimidazole quinolinones and uses thereof | BARSANTI PAUL A | 2009-11-12 | — | — | US | disclosed |
| US-20090181979-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF QUINOLINONE COMPOUNDS HAVING IMPROVED PHARMACEUTICAL PROPERTIES | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2009-07-16 | — | — | US | disclosed |
| US-20050209247-A1 | Lactate salt of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one; improved water solubility and physicochemical properties (e.g., stability, hygroscopicity, crystallinity, and compactibility); vascular endothelial growth factor receptor tyrosine kinase inhibitors | CHIRON CORPORATION | 2005-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281100-A1 | Benzimidazole quinolinones and uses thereof | GAA, ALPI, IL4I1 | OPRM1 2790/4885CNR1 4087/4885ALDH1A1 276/4885 |
| US-20130338171-A1 | Pharmaceutically Acceptable Salts of Quinolinone Compounds Having Improved Pharmaceutical Properties | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RAB14, SLC13A3 | OPRM1 1464/4885CNR1 1500/4885ALDH1A1 1479/4885 |
| US-20090181979-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF QUINOLINONE COMPOUNDS HAVING IMPROVED PHARMACEUTICAL PROPERTIES | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RAB14, SLC13A3 | OPRM1 1464/4885CNR1 1500/4885ALDH1A1 1479/4885 |
| US-20050209247-A1 | Lactate salt of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one; improved water solubility and physicochemical properties (e.g., stability, hygroscopicity, crystallinity, and compactibility); vascular endothelial growth factor receptor tyrosine kinase inhibitors | KDR, FLT4, FLT1 | OPRM1 3093/4885CNR1 2989/4885ALDH1A1 1023/4885 |
| US-20140303182-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF QUINOLINONE COMPOUNDS HAVING IMPROVED PHARMACEUTICAL PROPERTIES | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RAB14, SLC13A3 | OPRM1 1464/4885CNR1 1500/4885ALDH1A1 1479/4885 |
| US-20130018058-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF QUINOLINONE COMPOUNDS HAVING IMPROVED PHARMACEUTICAL PROPERTIES | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RAB14, SLC13A3 | OPRM1 1464/4885CNR1 1500/4885ALDH1A1 1479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.